NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
83257-0003-01 | 83257-0003 | Trastuzumab-dkst, Trastuzumab | OGIVRI | 420.0 mg/20mL | Immunotherapy | Monoclonal Antibody | HER2 | Intravenous | Oct 1, 2023 | In Use | |
74527-0022-03 | 74527-0022 | margetuximab-cmkb | MARGENZA | 25.0 mg/mL | Immunotherapy | Monoclonal Antibody | HER2 | Intravenous | Jan 15, 2021 | In Use | |
55513-0710-21 | 55513-0710 | Denosumab | Prolia | 60.0 mg/mL | Immunotherapy | Monoclonal Antibody | RANKL | Subcutaneous | Mar 5, 2024 | In Use | |
55513-0206-01 | 55513-0206 | Bevacizumab-awwb | MVASI | 100.0 mg/4mL, 100.0 mg/4mL | Immunotherapy | Monoclonal Antibody | VEGFR | Intravenous | Jun 1, 2018 | In Use | |
00069-0315-01 | 00069-0315 | Bevacizumab-bvzr | Zirabev | 100.0 mg/4mL | Immunotherapy | Monoclonal Antibody | VEGFR | Intravenous | Jan 13, 2020 | In Use | |
55513-0326-01 | 55513-0326 | rituximab-arrx | Riabni | 500.0 mg/50mL | Immunotherapy | Monoclonal Antibody | CD20 | Intravenous | Jan 6, 2021 | In Use | |
00069-2522-02 | 00069-2522 | Elranatamab-bcmm | Elrexfio | 44.0 mg/1.1mL | Immunotherapy | Monoclonal Antibody | BCMA, CD3 | Subcutaneous | Aug 15, 2023 | In Use | |
67457-0847-44 | 67457-0847 | Trastuzumab | OGIVRI | 420.0 mg/ 20 mL | Immunotherapy | Monoclonal Antibody | HER2 | Intravenous | Nov 29, 2019 | Apr 30, 2027 | In Use |
82705-0010-01 | 82705-0010 | Epcoritamab-bysp | EPKINLY | 48.0 mg/.8mL | Immunotherapy | Monoclonal Antibody | CD20, CD3 | Subcutaneous | May 19, 2023 | In Use | |
00069-0249-01 | 00069-0249 | Rituximab-pvvr | Ruxience | 500.0 mg/50mL | Immunotherapy | Monoclonal Antibody | CD20 | Intravenous | Jan 23, 2020 | In Use | |
55513-0224-01 | 55513-0224 | rituximab-arrx | Riabni | 100.0 mg/10mL | Immunotherapy | Monoclonal Antibody | CD20 | Intravenous | Jan 6, 2021 | In Use | |
50242-0245-01 | 50242-0245 | Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf | Phesgo | 30000.0 U/15mL, 1200.0 mg/15mL, 600.0 mg/15mL | Immunotherapy | Monoclonal Antibody | HER2 | Subcutaneous | Jun 29, 2020 | In Use | |
82143-0002-01 | 82143-0002 | Bevacizumab-tnjn | Avzivi | 400.0 mg/16mL | Immunotherapy | Monoclonal Antibody | VEGFR | Intravenous | Jan 1, 2025 | In Use | |
00069-4494-02 | 00069-4494 | Elranatamab-bcmm | Elrexfio | 76.0 mg/1.9mL | Immunotherapy | Monoclonal Antibody | BCMA, CD3 | Subcutaneous | Aug 15, 2023 | In Use | |
70121-1754-07 | 70121-1754 | Bevacizumab-maly | ALYMSYS | 100.0 mg/4mL | Immunotherapy | Monoclonal Antibody | VEGF | Intravenous | Apr 15, 2022 | In Use | |
57894-0502-20 | 57894-0502 | Daratumumab | Darzalex | 100.0 mg/5mL | Immunotherapy | Monoclonal Antibody | CD38 | Intravenous | Nov 16, 2015 | Nov 30, 2026 | In Use |
73042-0201-01 | 73042-0201 | Naxitamab | DANYELZA | 40.0 mg/10mL | Immunotherapy | Monoclonal Antibody | GD2 | Intravenous | Nov 25, 2020 | In Use | |
00173-0821-33 | 00173-0821 | Ofatumumab | Arzerra | 20.0 mg/mL | Immunotherapy | Monoclonal Antibody | CD20 | Intravenous | Jul 22, 2011 | Aug 31, 2017 | No Longer Used |
50242-0109-01 | 50242-0109 | Rituximab and hyaluronidase | Rituxan Hycela | 2000.0 U/mL, 2000.0 U/mL, 120.0 mg/mL | Immunotherapy | Monoclonal Antibody | CD20 | Subcutaneous | Jun 22, 2017 | In Use | |
00003-2291-11 | 00003-2291 | Elotuzumab | Empliciti | 300.0 mg/1 | Immunotherapy | Monoclonal Antibody | SLAMF7 | Intravenous | Nov 30, 2015 | In Use | |
00173-0821-02 | 00173-0821 | Ofatumumab | Arzerra | 20.0 mg/mL | Immunotherapy | Monoclonal Antibody | CD20 | Intravenous | Jul 22, 2011 | Aug 31, 2017 | No Longer Used |
83257-0004-12 | 83257-0004 | Trastuzumab-dkst | OGIVRI | Immunotherapy | Monoclonal Antibody | HER2 | Oct 1, 2023 | In Use | |||
57894-0450-01 | 57894-0450 | Teclistamab | TECVAYLI | 90.0 mg/mL | Immunotherapy | Monoclonal Antibody | BCMA, CD3 | Subcutaneous | Oct 25, 2022 | In Use | |
55513-0954-01 | 55513-0954 | Panitumumab | Vectibix | 100.0 mg/5mL | Immunotherapy | Monoclonal Antibody | EGFR | Intravenous | Oct 10, 2006 | In Use | |
50242-0145-01 | 50242-0145 | Pertuzumab | Perjeta | 30.0 mg/mL | Immunotherapy | Monoclonal Antibody | HER2 | Intravenous | Jun 8, 2012 | In Use |
Found 11465 results — Export these results